Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| GlaxoSmithKline | 2.57% | $467.58K | £88.76B | 48.36% | 77 Outperform | |
| ― | 2.53% | $459.24K | ― | ― | ― | |
| Roche Holding AG | 2.46% | $447.65K | CHF298.70B | 43.81% | 73 Outperform | |
| Bristol-Myers Squibb | 2.37% | $430.89K | $125.45B | 5.82% | 78 Outperform | |
| BAE Systems | 2.33% | $422.84K | £62.43B | 65.28% | 61 Neutral | |
| Yum China Holdings | 2.31% | $420.60K | $20.24B | 17.20% | 78 Outperform | |
| Melrose | 2.15% | $391.16K | £8.02B | 3.39% | 50 Neutral | |
| Koninklijke Philips N.V. | 2.14% | $389.54K | €25.29B | 5.25% | 56 Neutral | |
| Thales | 2.13% | $387.18K | €51.63B | 32.98% | 73 Outperform | |
| Spirax Group | 2.12% | $385.62K | £5.83B | 6.74% | 72 Outperform |